The economics of febrile neutropenia: implications for the use of colony-stimulating factors

By Lyman G.H.   Kuderer N.   Greene J.   Balducci L.  

European Journal of Cancer, Vol. 34, Iss. 12, 1998-11 ,pp. : 1857-1864

Elsevier

Access to resources Recommend Favorite

Febrile neutropenia, colony-stimulating factors and therapy: time for a new methodology?

By Forrest Graeme   Schimpff Stephen   Cross Alan  

Supportive Care in Cancer, Vol. 10, Iss. 3, 2002-04 ,pp. : 177-180

Springer Publishing Company

Access to resources Recommend Favorite

Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy

By Yakushijin Yoshihiro   Shikata Hisaharu   Takaoka Ikue   Horikawa Tamami   Takeuchi Kazuhito   Yamanouchi Jun   Azuma Taichi   Narumi Hiroshi   Hato Takaaki   Yasukawa Masaki  

International Journal of Clinical Oncology, Vol. 16, Iss. 2, 2011-04 ,pp. : 118-124

Springer Publishing Company

Access to resources Recommend Favorite

Prevalence and patterns of cytomegalovirus DNAemia in adult patients with acute lymphoblastic leukemia on chemotherapy

By Gulia Seema   Dangi Uma   Biswas Sanjay   Kelkar Rohini   Menon Hari   Sengar Manju  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1209-1211

Informa Healthcare

Access to resources Recommend Favorite

Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia

By Copland Mhairi  

Future Oncology, Vol. 5, Iss. 4, 2009-05 ,pp. : 455-458

Future Medicine

Access to resources Recommend Favorite